Inroduction: This study reports on our experience with transcatheter closure of perimembraneous ventricular septal defects (pm-VSDs) with Amplatzer duct occluder I (ADO I) and Amplatzer duct occluder II (ADO II) Methods: Transcatheter device implantation with ADO I and ADO II was attempted in 17 patients with pm-VSD between August 2014 to December 2015. We usually decided the appropriate type and size of device according to the measurements by left ventricular angiograms. We choose 1-2 mm larger device than the defect size in our first cases. Recently we prefered 2-4 mm larger device due to prevent the residuel leakage or device embolism. Results: Patient mean age was 10.59±3.55 years and mean weight was 37.12±16.36. The mean defect size was 5.17±1,66 mm , mean Qp/Qs was 1.88±0.5, mean PVR/SVR ratio was 0.042±0.028 and mean fluoroscopy time was 25.11±7.97 minutes. ADO I was used in 13 cases and ADO II used in remaining 4 patients. The Amplatzer duct occluders were succesfully implanted in 16 of 17 patients. In one patient, ADO I suddenly embolised into the left pulmonary artery soon after its release. This device was retrieved and the patient underwent surgical closure of the ventricular septal defect succesfully. One of 4 patients underwent pmVSD closure with ADO-II had residuel leakage and one of them had transient left bundle branch block after the procedure. In addition one of patient had residuel leakage after ADO I deployment. No atrioventricular block (AVB) was determined during follow-up.
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Conclusions: We prefer the Amplatzer duct occluders in percutenous closing to pm-VSD among several devices. Amplatzer duct occluder I has an advantage due to does not have a proximal disc and thus does not squeeze the AV bundles. Although ADO II has a two disc, its low-profile and flexibility provides some advantages compared to other devices. Residuel leakage and one case of device embolism were seen in our first cases. Therefore we started to choose 2-4 mm larger device if adaquete defect rims were present and no residual leakage, embolism or AVB were detected . Duct occluders provide an effective and safe treatment option in selected patients with pm-VSD
